The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study

Table 1

Patient characteristics.

Number of cases	140
Gender, (%), male : female	61 : 79 (43.6 : 56.4)
Age,
Age distribution, (%), ≤74 : ≥75	71 : 69 (50.7 : 49.3)
Laxative combination, (%)	76 (54.3)
Irritant laxative combination, (%)	34 (24.3)
Elobixibat dose (mg), (%), 5 : 10 : 15 : discontinuation	27 : 92 : 10 : 11 (19.3 : 65.7 : 7.1 : 7.9)
Underlying disease, (%)
Dyslipidemia	42 (30.0)
Diabetes	25 (17.9)
Hepatic disorder	10 (7.1)
Hypothyroidism	6 (4.3)
Parkinson’s disease	5 (3.6)
Concomitant medication, (%)
Antacids	55 (39.3)
Antidepressants	14 (10.0)
Calcium antagonists	11 (7.9)
Parkinson’s disease drugs	5 (3.6)
Opioids	4 (2.9)
Ursodeoxycholic acid	3 (2.1)

SD: standard deviation.